Skip to Main Content

Whither accelerated approval?

Amid the hubbub over new Medicare coverage restrictions for Alzheimer’s treatments, a key issue may not be fully appreciated: There is now bona fide pushback against accelerated approval, a controversial strategy used by regulators and companies to get new drugs to market faster than usual.


On its face, this suggests potentially wider — and sobering — implications for the pharmaceutical industry and patients, because they may one day have to wait longer for new medicines to get out the proverbial door.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.